Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Notch-mediated induction of N-cadherin and α 9-integrin confers higher invasive phenotype on rhabdomyosarcoma cells

  • Masià Fontana, Anna
  • Almazán-Moga, Anna
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Reventós, Jaume
  • Torán, Núria
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Roma, Josep|||0000-0001-7692-6123
  • Gallego, Soledad|||0000-0002-4712-9624
Rhabdomyosarcoma (RMS) is the commonest type of soft-tissue sarcoma in children. Patients with metastatic RMS continue to have very poor prognosis. Recently, several works have demonstrated a connection between Notch pathway activation and the regulation of cell motility and invasiveness. However, the molecular mechanisms of this possible relationship remain unclear. The Notch pathway was manipulated pharmacologically and genetically. The mRNA changes were analysed by quantitative PCR and protein variations by western blot and immunofluorescence. Finally, the capabilities of RMS cells to adhere, heal a wound and invade were assessed in the presence of neuronal cadherin (N-cadherin)- and α 9-integrin-blocking antibodies. Cells treated with γ -secretase inhibitor showed lower adhesion capability and downregulation of N-cadherin and α 9-integrin. Genetic manipulation of the Notch pathway led to concomitant variations in N-cadherin and α 9-integrin. Treatment with anti-N-cadherin-blocking antibody rendered marked inhibition of cell adhesion and motility, while anti- α 9-integrin-blocking antibody exerted a remarkable effect on cell adhesion and invasiveness. Neuronal cadherin and α 9-integrin are postulated as leading actors in the association between the Notch pathway and promotion of cell adhesion, motility and invasion, pointing to these proteins and the Notch pathway itself as interesting putative targets for new molecular therapies against metastases in RMS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Childhood and Adolescent Central Nervous System Tumours in Spain, Incidence and Survival over 20 Years: A Historical Baseline for Current Assessment

  • Chirlaque López , María Dolores
  • Peris-Bonet, Rafael|||0000-0002-4200-2309
  • Sánchez, Antonia
  • Cruz, Ofelia|||0000-0001-7102-3283
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Gutiérrez-Ávila, Gonzalo
  • Quirós García, José Ramón
  • Almela-Vich, Fernando
  • López de Munain, Arantza|||0000-0001-6820-9124
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Franch-Sureda, Paula
  • Ardanaz, Eva
  • Galceran, Jaume|||0000-0002-1584-7293
  • Martos, Carmen
  • Salmerón, Diego
  • Gatta, Gemma|||0000-0003-4160-6458
  • Botta, Laura
  • Cañete, Adela
Background: Central nervous system (CNS) neoplasms are highly frequent solid tumours in children and adolescents. While some studies have shown a rise in their incidence in Europe, others have not. Survival remains limited. We addressed two questions about these tumours in Spain: (1) Is incidence increasing? and (2) Has survival improved? Methods: This population-based study included 1635 children and 328 adolescents from 11 population-based cancer registries with International Classification of Childhood Cancer Group III tumours, incident in 1983-2007. Age-specific and age-standardised (world population) incidence rates (ASRws) were calculated. Incidence time trends were characterised using annual percent change (APC) obtained with Joinpoint. Cases from 1991 to 2005 (1171) were included in Kaplan-Meier survival analyses, and the results were evaluated with log-rank and log-rank for trend tests. Children's survival was age-standardised using: (1) the age distribution of cases and the corresponding trends assessed with Joinpoint; and (2) European weights for comparison with Europe. Results: ASRw 1983-2007: children: 32.7 cases/10; adolescents: 23.5 cases/10. The overall incidence of all tumours increased across 1983-2007 in children and adolescents. Considering change points, the APCs were: (1) children: 1983-1993, 4.3%^ (1.1; 7.7); 1993-2007, -0.2% (-1.9; 1.6); (2) adolescents: 1983-2004: 2.9%^ (0.9; 4.9); 2004-2007: -7.7% (-40; 41.9). For malignant tumours, the trends were not significant. 5-year survival was 65% (1991-2005), with no significant trends (except for non-malignant tumours). Conclusions: CNS tumour incidence in Spain was found to be similar to that in Europe. Rises in incidence may be mostly attributable to changes in the registration of non-malignant tumours. The overall malignant CNS tumour trend was compatible with reports for Southern Europe. Survival was lower than in Europe, without improvement over time. We provide a baseline for assessing current paediatric oncology achievements and incidence in respect of childhood and adolescent CNS tumours.